The presently disclosed subject matter provides methods and compositions for activation of clustered receptors on a target cell using nanocarrier-associated ligands, particularly methods and compositions for targeted activation of clustered receptors on antigen-experienced T cells using nanocarrier-associated antibodies.

The present invention relates to an anticancer T cell therapy product-assisting composition comprising a depleting anti-CD4 monoclonal antibody and a use thereof. Accordingly, the composition comprising a depleting anti-CD4 monoclonal antibody according to the present invention is able to maximize the anticancer effect of a cancer antigen-specific anticancer T cell therapy product by maintaining an immunodeficient state and is thus effective. In addition, when administered twice or more times at regular intervals of 5 to 8 days, the composition exhibits a far superior effect.

The present invention relates to an anticancer T cell therapy product-assisting composition comprising a depleting anti-CD4 monoclonal antibody and a use thereof. Accordingly, the composition comprising a depleting anti-CD4 monoclonal antibody according to the present invention is able to maximize the anticancer effect of a cancer antigen-specific anticancer T cell therapy product by maintaining an immunodeficient state and is thus effective. In addition, when administered twice or more times at regular intervals of 5 to 8 days, the composition exhibits a far superior effect.

Vaccine design, polycistronic vaccine constructs, compositions, and methods comprising nucleic acids (DNA, RNA), peptides, proteins and derivatives thereof, including cells and cell-lines, for enhanced antigen-specific vaccination.

The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.

The disclosure relates to methods of treating or preventing a disease in a subject by conjointly administering to the subject an arginase inhibitor disclosed herein and a composition comprising immune cells disclosed herein.

The disclosure relates to methods of treating or preventing a disease in a subject by conjointly administering to the subject an arginase inhibitor disclosed herein and a composition comprising immune cells disclosed herein.

The present invention provides a novel complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. Moreover, the present invention also provides a nucleic acid encoding such a complex, wherein the complex is a peptide or a protein. Such a nucleic acid may be comprised by a vector, and such a vector may be comprised by a host cell. In particular, compositions, such as a pharmaceutical compositions and vaccines are provided, which may be useful for example in the prevention and/or treatment of a diseases and/or a disorder including cancer, hematological disorders, infectious diseases, autoimmunity disorders and transplant rejections.

The present invention provides a cell penetrating peptide derived from ZEBRA, which is optionally linked to a cargo molecule, such as at least one antigen or antigenic epitope. The present invention also provides a complex comprising the cell penetrating peptide and the cargo molecule. In particular, compositions, such as a pharmaceutical compositions and vaccines are provided, which may be useful for example in the prevention and/or treatment of a diseases and/or a disorder including cancer, hematological disorders, infectious diseases, autoimmunity disorders and transplant rejections.

The present invention provides a novel complex for use in the prevention and/or treatment of colorectal cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of colorectal cancer, such as a pharmaceutical compositions and vaccines are provided.